EGFR and non-small cell lung carcinoma: A total of 973 patients with stage IB to IIIA NSCLC (AJCC 6th Edition), EGFR mutant + disease, were randomized in a 2:1 fashion to receive either erlotinib or placebo for a total of two years, with the primary endpoint of disease-free survival and a secondary endpoint of overall survival.